Apimeds Pharmaceuticals US (APUS) Consolidated Net Income (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) reported Consolidated Net Income of -$7.2 million for Q4 2025, down 2216.75% on a YoY basis from $341077.5 in Q4 2024, and down 302.41% quarter-over-quarter from -$1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Consolidated Net Income (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Consolidated Net Income for 2 years, with the latest figure at -$7.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Consolidated Net Income fell 2216.75% year-over-year to -$7.2 million; the trailing twelve-month figure through Dec 2025 stood at -$12.1 million (down 769.64% YoY), and the FY2025 full-year result was -$12.1 million, down 769.64% from the prior year.
  • Consolidated Net Income for Q4 2025 stood at -$7.2 million, down from -$1.8 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$296473.0 in Q1 2024, with the low at -$7.2 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 370.00 Mn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 601.00 Mn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 274.90 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -114,733.81
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 197.90 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 57.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -66.53 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -92.12 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 118.42 Mn
10 Apimeds Pharmaceuticals US 13.93 Mn 10.29 Mn - -7.22 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.22 Mn
Sep 30, 2025 -1.79 Mn
Jun 30, 2025 -2.67 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -311,633.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00